Moderna Raises Full-Year Growth Outlook to 15% to 25% After Q3 Earnings Beat

John Kim

1 min read

Add as a preferred source on Google

Moderna Raises Full-Year Growth Outlook to 15% to 25% After Q3 Earnings Beat

Higher overseas COVID-19 vaccine sales drove revenue growth and helped produce the third-quarter earnings beat.

By John Kim

Published Nov 9, 2026, 12:06 PM EST

Unmarked vaccine vials rest inside an insulated shipping case / TokenPost.ai

Moderna raised its full-year growth outlook to 15% to 25% after third-quarter results showed revenue growth and an earnings beat. Higher overseas sales of its COVID-19 vaccines drove the revenue growth and helped produce the earnings beat.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.